11 Recruiting Prostatic Neoplasms Phase 3 Clinical Trials
Active phase 3 studies for prostatic neoplasms enrolling across the USA. Verify eligibility and contact site coordinators.
All Prostatic Neoplasms studiesPhase 3 Studies for Prostatic Neoplasms
🔵 Active, Not Recruiting Phase3
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
📍 Clinical Research Facility — Homewood, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
📍 Clinical Research Facility — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
📍 Clinical Research Facility — Phoenix, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
📍 Arizona Oncology Associates, P.C. - HOPE — Prescott, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
📍 UC San Diego Moores Cancer Center — La Jolla, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
📍 Arizona Urology Specialists — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 / Phase3
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
📍 Columbia University Irving Medical Center — New York, New York
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
📍 Mayo Clinic - Arizona Mayo Clinic Hospital — Scottsdale, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
📍 Rocky Mountain Cancer Centers — Denver, Colorado
View Study & Checklist ➔